Loading company…
RIN Institute develops antibody therapeutics intended to improve cancer diagnosis and treatment, with a focus on oncology patients.
RIN Institute Inc., founded in 2016 in Tokyo, Japan, develops antibody therapeutics for cancer, including proprietary monoclonal antibodies meant to improve the efficacy and safety of treatment. Its products address needs such as late-stage diagnosis and limited treatment options, and its customers include hospitals, oncology clinics and research institutions, mainly in Asia. The company is at Series B stage and raised JPY 500.000 mn from Alfresa Holdings in May 2023, which it plans to use to support the Phase 1 study of its anti-TMEM180 antibody.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in